As of PACRG, it is remarkable that this gene resides within the FRA6E CFS, where also the tumour suppressor PARK2 is located, suggesting that the deletion associated with this CFS may concomitantly disrupt PARK2 and increase the expression of PACRG, whose tumourigenic role remains largely unknown. This evidence concerns the gene PRKN and neoplasm.